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Purpose. We recently reported an association of adult BMI change with colon cancer risk. Here, we sought to further explore this
association with respect to postmenopausal HRT use in a larger study population. Methods. We included 1,457 postmenopausal
women participating in an ongoing population-based case-control study of colon cancer. Results. We confirmed a previously
reported association of adulthood weight gain and increased risk of colon cancer: compared to those with <5 kg/m2 change of BMI,
women who reported moderate (5–10 kg/m2) and large (>10 kg/m2) BMI changes since their 20s had OR estimates of 1.54 (95%
CI = 1.09–2.19) and 1.45 (95% CI = 0.90–2.33), respectively (P for trend = 0.05). Stratified analyses showed that this association
was limited to HRT nonusers: ORs were 1.77 (95% CI = 1.02–3.05) and 2.21 (95% CI = 1.09–4.45), respectively (P for trend
= 0.03), for BMI changes occurring between the 20s decade and time of recruitment among non-users. Similar associations were
observed for BMI changes since the 30s decade. There was no association among HRT users. Conclusion. Our results suggest early
adulthood weight gain increases colon cancer risk in postmenopausal women who do not use HRT.
1. Introduction
Obesity and central adiposity, in particular, are now a well-
recognized risk factor for several malignancies including
colon cancer in both men and women [1–3]. Body mass
index (BMI) is commonly used to assess obesity (BMI ≥
30 kg/m2), and a large number of epidemiological studies
support a BMI-colon cancer risk association. This associ-
ation is generally stronger for men than that for women
[4–6], possibly due to sex differences in fat distribution
and/or hormonal milieus. Possible putative pathophysiologic
mechanisms for the positive association of obesity with colon
cancer include higher levels of circulating peptide hormones
such as insulin and insulin-like growth factor-1 (IGF-1),
adipose and gut hormones, inflammatory cytokines, free
radicals, fatty acid metabolites, and sex steroid hormones in
the obese [7, 8].
Both animal and human studies have demonstrated
modulatory effects of reproductive hormones on tumor cell
growth and proliferation [9–12] and estrogen, either endoge-
nously produced in premenopausal females or administered
exogenously in the form of hormone replacement therapy
(HRT), has been consistently shown to exert a protective
effect against colorectal cancer in women [4, 13, 14]. A num-
ber of epidemiological studies have shown that the obesity-
colon cancer risk association is stronger in pre-menopausal
women as compared to postmenopausal women [1, 15, 16],
suggesting an interactive effect of obesity and estrogen in the
development of colon cancer.
We have previously demonstrated increased colon cancer
risk for men and women with BMIs over ≥30 kg/m2 at time
of recruitment as well as for large BMI changes (≥10 kg/m2)
during the 30s or 20s decades in women [17]. These results
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further strengthened the evidence for the role of obesity
in increasing colon cancer risk, and suggest that adulthood
BMI changes may be a sensible measure of obesity-related
colon cancer risk in women. However, no studies have
examined how changes in BMI over time might be affected
by HRT use among postmenopausal women in colon cancer
development. Therefore, we evaluated potential associations
between BMI and changes in adult BMI over time (since
20s, 30s, 40s, 50s, and 2 years before study recruitment
(“current”)) and colon cancer risk in 1,457 postmenopausal
women participating in a population-based case-control
study. We hypothesize that HRT use may offset the risk effect
of adult weight gain to the extent that the risk associated with
large adult BMI change and colon cancer will be diminished
in postmenopausal women taking HRT, as compared to those
not taking HRT.
2. Methods and Procedures
2.1. Study Population. The Kentucky colon cancer genetic
epidemiology study has been described previously [17]. The
present analysis is based on patients recruited through May
2011. Briefly, patients with newly diagnosed colon cancer
(rectal cancer excluded) were identified from the Kentucky
Cancer Registry, a participant in the National Cancer Insti-
tute’s Surveillance, Epidemiology, and End Results (SEER)
Program as well as the Centers for Disease Control and Pre-
vention’s National Program of Cancer Registries. The registry
database was reviewed quarterly and all primary incident
colon cancer cases were identified and invited to participate
in the study via mailed letter. They were then called approxi-
mately 3 weeks later and interviewed to determine eligibility.
We excluded patients with known history of inflammatory
bowel disease (IBD), family history of familial adenomatous
polyposis (FAP), and hereditary nonpolyposis colorectal
cancer (HNPCC).
Population controls were recruited via random digit
dialing throughout the state of Kentucky. Area codes and
exchanges of cases were utilized with random digit genera-
tion of the remaining four digits. Among those reached, tel-
ephone screening was employed to determine eligibility.
The controls were at least 40 years of age and could not
have had any personal history of nonskin cancer. Additional
exclusion criteria included history of IBD, FAP, and HNPCC.
Of those who answered the phone and allowed eligibility
determination, 70.8% of cases and 66.7% of controls agreed
to participate in the study. The Institutional Review Boards
of the University of Kentucky, Lexington and University
Hospitals Case Medical Center approved the study and all
participants provided written informed consent. For this
analysis, we included postmenopausal women only (516
cases, and 941 controls), excluding 190 women who were
premenopausal at the time of recruitment and all 1,125 male
participants from the dataset.
2.2. Data Collection. Eligible cases and controls were sent
a lifestyle risk factor questionnaire developed by the
National Cancer Institute Colon Cancer Familial Cancer
Registry https://bioinformatics.dartmouth.edu/ccfrc/Down-
loads/RFQ.pdf. This survey includes questions on height
and weight throughout the 20s, 30s, 40s, since the age of
50, and 2 years prior to diagnosis for cases and the previous 2
years for controls (“current”). BMI categories were calculated
based on World Health Organization definition as follows:
normal (BMI ≥ 18.5 to <25 kg/m2); overweight (BMI ≥ 25
to <30 kg/m2); obese BMI ≥ 30) [18]. Changes in BMI
were categorized as “Small” <5 kg/m2 (weight gain of ap-
proximately <25 lbs); “Moderate” 5–10 kg/m2 (approximate
weight gain of 25–50 lbs), and “Large” >10 kg/m2 (weight
gain exceeding 50 lbs).
Menopausal status was defined as cessation of menses for
12 months or longer prior to the recruitment. Bleeding re-
sulting from HRT, progestin, or withdrawal from such, was
not considered menstrual bleeding. Seven women who tem-
porarily stopped menstruating or who ceased bleeding due
to hysterectomy (without concomitant oophorectomy), radi-
ation, and/or chemotherapy were excluded from the analysis.
Family history of colorectal cancer was defined as any
history in a first degree relative of colorectal cancer. Smoking
was classified as “ever” versus “never” based on cigarette
smoking of at least one cigarette per day for 3 months or
longer. Alcohol use was based on patient response (“yes” ver-
sus “no”) to history of consumption of any alcoholic bever-
age at least once a week for 6 months or longer. Nonsteroidal
anti-inflammatory drug (NSAID) use was defined as use of
medications, such as aspirin or ibuprofen (brand or generic)
at least twice weekly for 6 months or more. Physical activity
(PA) was assessed using intensity because information on
frequency and duration across the decades was not suffi-
ciently available. We assigned metabolic equivalent values
(metabolic activity of task or METs) to the activity and
categorized intensity into Light (1 to <3 METs), moderate
(3× 6 METs), or vigorous (>6 METs) [19, 20].
2.3. Statistical Analysis. We first examined all variables of
interest univariately for association with colon cancer risk in
our sample. Continuous variables were evaluated using a
standard student’s t-test; categorical variables were evaluated
using a chi-square test.
We then used unconditional logistic regression modeling
to evaluate the potential associations between overweight
and obesity compared to normal body size and colon cancer
risk in each decade (20s, 30s, 40s, 50s, and current). All
analyses were adjusted for potential confounding by other
known colon cancer risk factors including age, race, educa-
tion, income, physical activity, family history of colon cancer,
smoking, alcohol, nonsteroidal anti-inflammatory drug use,
age at menarche, and parity.
Changes in BMI over time were calculated for each
individual for different age decades through the time of
recruitment. These were categorized into “Small, Moderate,
and Large” changes as described in the data collection sec-
tion. Those with “Small” BMI changes were used as the
referent group. In logistic regressions, we adjusted for all
variables included in the logistic regression models for BMI,
and additionally adjusted for current BMI. These logistic
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regressions were then stratified by HRT use to evaluate dif-
ferential association of BMI changes by HRT use. We exam-
ined the interaction of HRT use and weight change by adding
into the full regression model a cross-product term of HRT
and weight change during various age decades. Significance
testing was based on likelihood ratio tests with one degree of
freedom.
All P values are from two-sided tests and P values < 0.05
were considered statistically significant. All analyses were
undertaken using SAS (Version 8.2, SAS Institute, Cary, NC,
USA).
3. Results
Characteristics of the participants included in the present
analysis are summarized in Table 1. Mean age for the cases
(63.8 years) was similar to controls (63.4 years) (P =
0.38). There were significant differences with respect to
education and income, with controls tending toward both
higher educational attainment and higher incomes (Table 1).
Controls were also significantly more likely to drink alcohol
and to smoke than were cases. Cases, however, were more
likely to have a family history of colorectal cancer (P = 0.004)
and less likely to use NSAIDs than controls (P = 0.003). Use
of HRT was significantly lower in cases (P < 0.001). The
two groups did not differ significantly with respect to race
or physical activity levels during the 20s, 30s, or 50s decades
(P > 0.05).
Table 2 summarizes the results of the logistic regression
models to evaluate the association of BMI at different ages on
colon cancer risk. In the overall sample, there were no statis-
tically significant associations for BMI reported at different
age decades or up to 2 years prior to recruitment. Stratified
analyses by HRT use only revealed a statistically significant
increase of risk of colon cancer in obese postmenopausal
women who used HRT (OR= 1.74; 95% CI= 1.08–2.80).
Table 3 summarizes the association of changes in BMI
over age decades and colon cancer risk with and without
stratification by HRT use. Among all women, weight gain
or BMI changes taking place during the 20s and 30s decades
moderately, but statistically significantly, increased risk for
colon cancer (P for trend = 0.05 and = 0.02, resp.). Stratified
analyses revealed that the increase of risk for weight gain
or BMI changes taking place during both age decades was
limited to postmenopausal women not using HRT, with a
greater than 2 fold increase of colon cancer risk for large BMI
change (>10 kg/m2) in the 20s age decade (OR= 2.21; 95%
CI= 1.09–4.45; P for trend = 0.02). There was no evidence for
statistically significant association among postmenopausal
women reporting HRT use. HRT use itself was statistically
significantly associated with a decreased risk of colon cancer
in both univariate and fully adjusted analyses (data not
shown).
4. Discussion
We have previously shown that large adult weight gain or
BMI changes taking place in the 20s or 30s age decade
significantly increased the risk of colon cancer independent
of current BMI (within 2 years prior to recruitment),
particularly among women [17]. Our previous report was
based on 438 cases (212 women) and 491 controls (380
women). In the current study, based on a much larger
sample size of postmenopausal women (516 cases and 941
controls), we confirmed our previous results. Taken together,
these results suggest that weight gain occurring since early
adulthood may be a rational indicator of visceral adiposity
accumulation and an important phenotypic marker for
assessing obesity-related colon cancer risk in women.
BMI is commonly used in epidemiological studies to
assess degree of obesity, and the BMI-colon cancer associ-
ation has consistently been found to be stronger in men
than in women [1, 21–24]. In the current study, we found
that overall there is no colon cancer risk association for
BMI reported for most of the age decades or 2 years prior
to recruitment. The statistically significant association for
obesity (BMI ≥ 30 kg/m2) reported for the 50s age decade
among HRT users is somewhat unexpected. Given that
there is no consistent pattern of risk increase (OR= 0.95 for
overweight (BMI ≥ 25 to < 30 kg/m2)) in this nor in any
other age decade, we believe this is likely due to chance.
It is speculated that central adiposity is the major driver
for increased circulating levels of insulin, IGFs, and inflam-
matory cytokines, as well as decreased levels of IGF binding
proteins—all of which have been implicated as tumor-
promoting [8, 25–29]. As a result, some have advocated
that alternative methods for body size characterization such
as waist-hip ratio (WHR) and waist circumference may
more accurately reflect abdominal obesity [30]. Other studies
have failed to demonstrate any increased association of
WHR or waist circumference, as compared to BMI, with
colorectal cancer in women [31] thereby arguing against
body fat distribution as the sole determinant of gender-based
differences in CRC risk.
Consistent with our hypothesis of opposing effects of
adult weight gain and HRT use, we have found that the
increased risk of colon cancer associated with weight gain
since early adulthood was largely limited to postmenopausal
women reporting no prior use of HRT. Although testing
for multiplicative interaction between BMI change and HRT
use was not statistically significant, this was likely due to
limited power in our study. HRT non-users with “Large”
BMI changes during their 20s were more than twice as likely
to develop colon cancer. Similarly, this same group of women
had a 77% increased risk of colon cancer if they experienced
even “Moderate” changes in BMI beginning in their 20s.
Likewise, both “Moderate” and “Large” BMI change between
the 30s decade and recruitment was associated with a
higher risk of colon cancer, though this association was
only statistically significant for those reporting “Moderate”
changes (P for trend 0.05). Smaller numbers in the “Large”
BMI change category for this age decade may have resulted
in the nonsignificant finding.
These findings confirm earlier studies showing that HRT
use may modify the effects of obesity in postmenopausal
women [16] possibly by counteracting the known risks
of weight gain during the early premenopausal years [2].
Modification of weight gain-associated CRC risk by use of
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Table 1: Characteristics of the Kentucky colon cancer genetic
epidemiology study postmenopausal females.
Characteristic
Cases
(N = 516)
Controls
(N = 941) P value
a
Age (years) 63.8 (8.9)b 63.4 (9.4)b 0.38
Race
Caucasian 483 (93.6%) 878 (93.3%) 0.43
African American 24 (4.7%) 54 (5.7%) —
Other 8 (1.6%) 7 (0.7%) —
Unknown 1 (0.2%) 2 (0.2%)
Education
<8 years 16 (3.1%) 8 (0.9%) <0.001
8–11 years 62 (12.0%) 78 (8.3%) —
High school
(HS) diploma
165 (32.0%) 260 (27.6%) —
Some post-HS training 165 (32.0%) 318 (33.8%) —
Bachelor’s degree 43 (8.3%) 114 (12.1%) —
Graduate degree 65 (12.6%) 163 (17.3%) —
Income
<$15,000 89 (17.2%) 118 (12.5%) <0.001
$15,000–$29,000 122 (23.6%) 174 (18.5%) —
$30,000–$44,000 93 (18.0%) 182 (19.3%) —
$45,000–$69,000 96 (18.6%) 164 (17.4%) —
≥$70,000 83 (16.1%) 229 (24.3%) —
Refused 33 (6.4%) 74 (7.8%) —
Cigarette smoker
Ever 244 (47.2%) 460 (48.9%) 0.04
Never 262 (50.8%) 476 (50.6%)
Unknown 10 (1.9%) 5 (0.5%)
Alcohol drinker
Yes 147 (28.5%) 353 (37.5%) <0.001
No 354 (68.6%) 550 (58.4%)
Unknown 15 (2.9%) 38 (4.0%)
Family history of colorectal
cancer
Yes 192 (37.2%) 276 (29.3%) 0.004
No 295 (57.2%) 588 (62.5%)
Unknown 29 (5.6%) 77 (8.2%)
NSAIDs use
Yes 189 (36.6%) 420 (44.6%) 0.003
No 327 (63.4%) 521 (55.4%)
HRT
Yes 222 (43.0%) 573 (60.9%) <0.001
No 290 (56.2%) 356 (37.8%)
Unknown 4 (0.8%) 12 (1.3%)
Physical activity
20s Light intensityc 76 (14.7%) 133 (14.1%) 0.80
Moderate intensityc 391 (75.8%) 709 (75.3%) —
Vigorous intensityc 49 (9.5%) 99 (10.5%) —
Table 1: Continued.
Characteristic
Cases
(N = 516)
Controls
(N = 941) P value
a
30s Light intensityc 72 (14.0%) 120 (12.8%) 0.20
Moderate intensityc 411 (79.7%) 737 (78.3%) —
Vigorous intensityc 33 (6.4%) 84 (8.9%) —
50s Light intensityc 96 (18.6%) 208 (22.1%) 0.19
Moderate intensityc 398 (77.1%) 685 (72.8%) —
Vigorous intensityc 22 (4.3%) 48 (5.1%) —
aP value for t-test or χ2-test with k (number of groups)—1 degrees of
freedom. bMean and SD of the mean in parentheses. cLight intensity: 1 to
<3.0 metabolic equivalents (METs); moderate intensity:≥3.0 to≤6.0 METs;
vigorous intensity: >6.0 METs.
exogenous HRT may be partly explained by the opposing
effects of HRT and adiposity on circulating levels of insulin
and IGF-1, and endogenous sex hormones such as estrogen.
Higher levels of insulin and bioactive IGF-1 are both
established risk factors for colon cancer and are believed to
at least partially account for the obesity-associated increased
risk of colon cancer [32]. HRT use decreases hepatic synthesis
of insulin-IGF-1 axis factors [33, 34], thus offsetting the
insulin-IGF-1 mediated colon carcinogenic effect of adipos-
ity. HRT use also increases the synthesis of sex hormone
binding globulin, leading to reduced circulating levels of
bioavailable endogenous estrogen [35]. In postmenopausal
women, adipose tissue is the main source of endogenous
estrogen production. Accumulating evidence suggests that in
contrast to the well established protective effects of HRT use
against colon carcinogenesis, increased lifetime exposure to
and high circulating levels of endogenous estrogen promote
the development of colon cancer [32, 36–38]. It is thus
plausible that HRT use may offset obesity-associated risk of
colon cancer by reducing the circulating levels of bioavailable
endogenous estrogen in postmenopausal women.
Study limitations include the possibility for information
bias from our case-control study design as well as potential
recall bias inherent in the use of self-reported height and
weight to calculate BMI. However, correlations between self-
reported and actual measured weight are generally quite high
[39, 40]. Additionally, in elderly patients, accurate recall of
self-reported weight has been demonstrated for as long as
28 years prior [41]. The modest participation of controls
recruited through random digit dialing was another study
limitation. Random digit dialing, although still prone to
selection bias, because of preference toward individuals with
landlines, was the most feasible method through which
recruitment of a sample most representative of our case
source population (State of Kentucky) could be achieved.
All analyses were adjusted, however, for well established risk
factors including education and income using very finely
defined categories.
In summary, our results confirm earlier findings of
the protective role of HRT in CRC and suggest that, in
postmenopausal women, HRT may ameliorate the negative
effects of early pre-menopausal weight gain to some extent.
This finding is of paramount clinical importance, especially
Journal of Obesity 5
T
a
bl
e
2:
O
dd
s
ra
ti
os
(O
R
s)
of
co
lo
n
ca
n
ce
r
fo
r
B
M
I
by
ag
e,
de
ca
de
sa
.
A
ll
po
st
m
en
op
au
sa
lw
om
en
Po
st
m
en
op
au
sa
lw
om
en
w
it
h
n
o
H
R
T
Po
st
m
en
op
au
sa
lw
om
en
w
it
h
H
R
T
C
as
e/
co
n
tr
ol
O
R
P
P
∗
C
as
e/
co
n
tr
ol
O
R
P
P
∗
C
as
e/
co
n
tr
ol
O
R
P
P
∗
N
or
m
al
c
(r
ef
)
14
7/
31
5
1.
00
—
72
/1
05
1.
00
—
75
/2
10
1.
00
—
B
M
I
2
yr
sb
O
ve
rw
ei
gh
t
15
9/
30
2
0.
98
(0
.7
3–
1.
32
)
0.
88
87
/1
17
0.
95
(0
.6
0–
1.
49
)
0.
82
72
/1
85
1.
01
(0
.6
7–
1.
52
)
0.
96
O
be
se
18
8/
27
9
1.
25
(0
.9
2–
1.
69
)
0.
16
0.
19
12
0/
12
3
1.
39
(0
.8
9–
2.
17
)
0.
15
0.
11
68
/1
56
1.
21
(0
.7
8–
1.
87
)
0.
39
0.
57
N
or
m
al
(r
ef
)
19
2/
41
0
1.
00
—
10
1/
14
5
1.
00
—
91
/2
65
1.
00
—
B
M
I
50
s
O
ve
rw
ei
gh
t
12
5/
24
2
0.
96
(0
.7
4–
1.
32
)
0.
77
73
/9
1
1.
06
(0
.6
8–
1.
65
)
0.
79
52
/1
51
0.
95
(0
.5
8–
1.
40
)
0.
66
O
be
se
12
6/
16
3
1.
27
(0
.9
7–
1.
92
)
0.
07
0.
19
70
/7
9
1.
18
(0
.7
2–
1.
93
)
0.
50
0.
64
56
/8
4
1.
74
(1
.0
8–
2.
80
)
0.
02
0.
08
N
or
m
al
(r
ef
)
25
0/
52
9
1.
00
—
12
7/
19
2
1.
00
—
12
3/
33
7
1.
00
—
B
M
I
40
s
O
ve
rw
ei
gh
t
10
1/
17
6
1.
07
(0
.7
8–
1.
47
)
0.
66
57
/6
4
1.
29
(0
.8
0–
2.
07
)
0.
30
44
/1
12
1.
01
(0
.6
5–
1.
59
)
0.
93
O
be
se
71
/1
14
1.
25
(0
.8
5–
1.
82
)
0.
26
0.
43
43
/5
9
1.
18
(0
.6
9–
2.
00
)
0.
54
0.
81
28
/5
5
1.
45
(0
.8
2–
2.
57
)
0.
20
0.
25
N
or
m
al
(r
ef
)
30
6/
62
9
1.
00
—
15
9/
22
7
1.
00
—
14
7/
40
2
1.
00
—
B
M
I
30
s
O
ve
rw
ei
gh
t
66
/1
15
1.
06
(0
.7
4–
1.
52
)
0.
76
37
/5
2
1.
02
(0
.6
0–
1.
72
)
0.
95
29
/6
3
1.
11
(0
.6
5–
1.
87
)
0.
71
O
be
se
42
/5
6
1.
42
(0
.9
0–
2.
27
)
0.
13
0.
90
27
/2
7
1.
50
(0
.8
0–
2.
83
)
0.
21
0.
47
15
/2
9
1.
38
(0
.6
8–
2.
83
)
0.
38
0.
76
N
or
m
al
(r
ef
)
33
3/
65
0
1.
00
—
17
8/
25
0
1.
00
—
15
3/
40
0
1.
00
—
B
M
I
20
s
O
ve
rw
ei
gh
t
48
/7
4
1.
15
(0
.7
6–
1.
75
)
0.
50
29
/3
0
1.
32
(0
.7
3–
2.
40
)
0.
35
19
/4
4
1.
10
(0
.6
0–
2.
02
)
0.
77
O
be
se
18
/3
6
0.
87
(0
.4
7–
1.
63
)
0.
67
0.
50
13
/2
0
0.
85
(0
.3
8–
1.
87
)
0.
68
0.
20
5/
16
0.
91
(0
.3
1–
2.
65
)
0.
86
0.
93
a A
dj
u
st
ed
fo
r
ag
e,
ra
ce
,g
en
de
r,
ed
u
ca
ti
on
,i
n
co
m
e,
ph
ys
ic
al
ac
ti
vi
ty
,s
m
ok
in
g,
al
co
h
ol
,n
on
st
er
oi
da
la
n
ti
-i
n
fl
am
m
at
or
y
dr
u
gs
u
se
,f
am
ily
h
is
to
ry
of
co
lo
re
ct
al
ca
n
ce
r,
ag
e
at
m
en
ar
ch
e,
an
d
pa
ri
ty
.b
2
ye
ar
s
be
fo
re
re
cr
u
it
m
en
t/
in
te
rv
ie
w
.c
N
or
m
al
:≥
18
.5
to
<
25
kg
/m
2
;o
ve
rw
ei
gh
t:
≥2
5
to
<
30
kg
/m
2
;o
be
se
:≥
30
kg
/m
2
.∗
P
va
lu
e
fo
r
tr
en
d.
6 Journal of Obesity
T
a
bl
e
3:
O
dd
s
ra
ti
os
(O
R
s)
of
co
lo
n
ca
n
ce
r
fo
r
ch
an
ge
s
in
B
M
I
ov
er
ti
m
e
by
ag
e,
de
ca
de
sa
.
A
ll
po
st
m
en
op
au
sa
lw
om
en
Po
st
m
en
op
au
sa
lw
om
en
w
it
h
n
o
H
R
T
Po
st
m
en
op
au
sa
lw
om
en
w
it
h
H
R
T
kg
/m
2
C
as
e/
co
n
tr
ol
O
R
P
P
∗
C
as
e/
co
n
tr
ol
O
R
P
P
∗
C
as
e/
co
n
tr
ol
O
R
P
P
∗
C
h
an
ge
in
B
M
I
in
50
s
<
5
(r
ef
)c
36
6/
69
1
1.
00
—
—
18
9/
25
9
1.
00
—
—
17
7/
43
2
1.
00
—
—
5–
10
57
/9
1
0.
92
(0
.6
1–
1.
40
)
0.
71
—
42
/4
2
1.
15
(0
.6
6–
1.
99
)
0.
62
—
15
/4
9
0.
67
(0
.1
7–
2.
65
)
0.
42
—
>
10
12
/2
3
0.
62
(0
.2
7–
1.
43
)
0.
26
0.
47
9/
11
0.
72
(0
.2
4–
2.
16
)
0.
56
0.
90
3/
12
1.
02
(0
.6
6–
1.
58
)
0.
57
0.
47
C
h
an
ge
in
B
M
I
in
40
s
<
5
(r
ef
)
28
6/
58
7
1.
00
—
—
14
2/
20
8
1.
00
—
—
14
4/
37
9
1.
00
—
—
5–
10
10
5/
19
2
0.
90
(0
.6
4–
1.
26
)
0.
55
—
63
/8
5
0.
86
(0
.5
3–
1.
40
)
0.
54
—
42
/1
07
0.
93
(0
.5
6–
1.
52
)
0.
76
—
>
10
35
/5
1
0.
98
(0
.5
7–
1.
69
)
0.
95
0.
88
23
/2
8
0.
82
(0
.3
9–
1.
70
)
0.
59
0.
59
12
/2
3
1.
24
(0
.5
4–
2.
86
)
0.
62
0.
65
C
h
an
ge
in
B
M
I
in
30
s
<
5
(r
ef
)
19
7/
47
3
1.
00
—
—
94
/1
71
1.
00
—
—
10
3/
30
2
1.
00
—
—
5–
10
15
8/
25
6
1.
48
(1
.0
6–
2.
07
)
0.
02
—
94
/9
8
1.
91
(1
.1
6–
3.
17
)
0.
01
—
64
/1
58
1.
22
(0
.7
6–
1.
95
)
0.
41
—
>
10
72
/1
09
1.
51
(0
.9
4–
2.
43
)
0.
09
0.
02
44
/5
0
1.
79
(0
.9
0–
3.
55
)
0.
10
0.
04
98
28
/5
9
1.
57
(0
.7
9–
3.
12
)
0.
20
0.
10
C
h
an
ge
in
B
M
I
in
20
s
<
5
(r
ef
)
15
2/
36
8
1.
00
—
—
77
/1
38
1.
00
—
—
75
/2
30
1.
00
—
—
5–
10
18
2/
31
3
1.
54
(1
.0
9–
2.
19
)
0.
02
—
91
/1
10
1.
77
(1
.0
2–
3.
05
)
0.
04
—
91
/2
03
1.
41
(0
.8
8–
2.
27
)
0.
16
—
>
10
12
2/
18
5
1.
45
(0
.9
0–
2.
33
)
0.
12
0.
04
9
83
/8
1
2.
21
(1
.0
9–
4.
45
)
0.
03
0.
02
39
/1
04
1.
11
(0
.5
6–
2.
19
)
0.
76
0.
38
a A
dj
u
st
ed
fo
r
ag
e,
ra
ce
,g
en
de
r,
ed
u
ca
ti
on
,i
n
co
m
e,
ph
ys
ic
al
ac
ti
vi
ty
,s
m
ok
in
g,
al
co
h
ol
,n
on
st
er
oi
da
la
n
ti
-i
n
fl
am
m
at
or
y
dr
u
gs
u
se
,f
am
ily
h
is
to
ry
of
co
lo
re
ct
al
ca
n
ce
r,
ag
e
at
m
en
ar
ch
e,
an
d
pa
ri
ty
.A
n
al
ys
is
ad
di
ti
on
al
ly
ad
ju
st
ed
fo
r
ba
se
lin
e
B
M
I
(B
M
I
in
th
e
“r
ec
ru
it
m
en
t
pe
ri
od
,”
2
ye
ar
s
be
fo
re
re
cr
u
it
m
en
t)
.c
<
5
kg
/m
2
(w
ei
gh
t
ga
in
of
ap
pr
ox
im
at
el
y
<
25
lb
s)
;5
–1
0
kg
/m
2
(w
ei
gh
t
ga
in
of
∼2
5–
50
lb
s)
an
d
>
10
kg
/m
2
(w
ei
gh
t
ga
in
ex
ce
ed
in
g
50
lb
s)
.∗
P
va
lu
e
fo
r
tr
en
d.
Journal of Obesity 7
in light of the fact that the use of hormone replacement
has declined significantly since the Women’s Health Initiative
study findings were published in 2002 [42, 43]. Further study
is warranted to evaluate why earlier versus later weight gain is
so strongly associated with increased CRC risk. Furthermore,
a deeper understanding of the exact biological mechanisms
via which HRT may modify CRC risk due to obesity
throughout adult life is necessary. Prospective studies in both
pre- and postmenopausal women of various body sizes, and
with varying types of fat distribution patterns, employing
serum biomarkers such as insulin, IGF-1, estrogen, and how
they change over time will be most instructive.
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